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Abstract 6 
  In recent years there has been a drive to create experimental techniques that can facilitate the 7 
accurate and precise prediction of transdermal permeation without the use of in vivo studies. This 8 
review considers why permeation data is essential, provides a brief summary as to how skin acts as a 9 
natural barrier to permeation and discusses why in vivo studies are undesirable. This is followed by an 10 
in-depth discussion on the extensive range of alternative methods that have been developed in recent 11 
years. All of the major ‘skin mimic systems’ are considered including: in vitro models using synthetic 12 
membranes, mathematical models including quantitative structure-permeability relationships 13 
(QSPRs), human skin equivalents and chromatographic based methods. All of these model based 14 
systems are ideally trying to achieve the same end-point, namely a reliable in vitro-in vivo correlation, 15 
i.e. matching non-in vivo obtained data with that from human clinical trials. It is only by achieving 16 
this aim, that any new method of obtaining permeation data can be acknowledged as a potential 17 
replacement for animal studies, for the determination of transdermal permeation. In this review the 18 
relevance, and potential applicability, of the various model systems will also be discussed. 19 
Introduction 20 
  Skin is a natural barrier yet, for many years has been a desirable route of administration for 21 
therapeutic drugs. For any cosmetic skincare product, environmental, or pharmaceutical compound, it 22 
is vital to know both the rate, and extent, of transdermal permeation to satisfy regulatory authorities. 23 
There are several ways the required data can be acquired, broadly categorized into in vivo, ex vivo and 24 
in vitro models (1). For all products that are intended for percutaneous permeation the main intention 25 
is optimisation of the drug and formulation to achieve maximum in vivo performance. Ideally, human 26 
studies would be undertaken to ascertain such information. However, this is not normally feasible 27 
during development. Thus, researchers resort to the aforementioned models. Until recent years, the 28 
majority of studies in this area utilised a wide variety of animals, mainly rodents (2), to obtain drug 29 
permeation data which can then be used as a basis to predict clinical outcomes. Although the volume 30 
of data that has arisen from such in vivo work has been beneficial in the development of some 31 
pharmaceutical products, there is a clear trend to move away from animal studies (3) for three main 32 
reasons. Firstly, ethical issues surrounding the use of live animals is a major incentive to consider 33 
other testing methods. This is especially true in the EU and several other markets where it is already 34 
no longer permissible for cosmetic product testing to involve the use of animals, with further 35 
restrictions to follow (4). Although their use in the pharmaceutical industry is still permissible, there is 36 
a clear move towards avoiding animal studies where possible. Secondly, researchers are adopting skin 37 
mimic systems because the animal study data that does exist cannot easily be compared and analysed 38 
across experimental studies as a result of the diverse range of animals used in research. Even within 39 
datasets from similar species the results may vary so considerably that comparative analysis is 40 
impossible, even within human studies inter-individual variation can be an issue (5, 6). The third, and 41 
possibly the most compelling, reason that transdermal permeation studies may avoid the use of 42 
animals is a lack of clear correlation between animal and human clinical trial data. For example, it has 43 
been shown that rodent skin generally shows higher permeation rates than human skin, often leading 44 
to incorrect conclusions from experimental data (7). Porcine skin, particularly that from the ear, is 45 
used in permeation studies as it has been shown to have similar properties to human skin (8) yet full 46 
animal studies with pigs are not ideal for the reasons previously outlined. 47 
 The outermost layer of human skin is the stratum corneum and is the main barrier for 48 
transdermal permeation. In human stratum corneum, the major lipid classes are ceramides, cholesterol 49 
and saturated long chain free fatty acids (9). Lipid organisation is fundamental to skin barrier 50 
function, for example in diseased or dry skin the lipid composition is different from that in healthy 51 
subjects. However, the specific details regarding lipid organisation within the stratum corneum are not 52 
fully understood, although it is accepted they will have an influence on transdermal permeation (10). 53 
It should be noted that in some cases it is not transdermal permeation that is desired but dermal 54 
absorption, i.e. delivery within particular regions of the skin itself – see ref. (11-13) for examples. In 55 
such circumstances transdermal permeation must still be measured, and considered, to satisfy 56 
regulators regardless of whether permeation is the intended outcome or not. For dermal delivery 57 
studies, drug permeation and distribution is not as specifically focused on the stratum corneum 58 
permeation as transdermal studies, but will also consider the deeper layers individually, namely viable 59 
epidermis and dermis. These are not so relevant to transdermal research as it is often assumed that 60 
stratum corneum penetration is the rate limiting step in permeation and must therefore be the focus of 61 
such studies.  62 
Skin permeability is closely linked with the hydrophobicity/hydrophilicity of the molecule in 63 
question. In general, researchers have shown that skin permeability decreases with increasing 64 
hydrophilicity, as expected based on the lipidic structure of the skin (14). Furthermore, the rate and 65 
extent of transdermal permeation is dependent upon several other factors including product 66 
formulation, location of application, temperature (15, 16), volume applied and skin integrity. Recent 67 
studies have begun to substantiate the importance of formulation and the considerable impact it may 68 
have on permeation (17, 18) yet much work is still to be done to fully understand the relationships 69 
involved.  70 
 This article reviews recent developments and current trends in the variety of methods reported 71 
to determine transdermal permeation data, avoiding the use of in vivo studies. Collectively, all such 72 
techniques can be referred to as ‘skin mimic systems’ yet individually they are comparatively diverse, 73 
subdivided into: 74   In vitro models using synthetic membranes 75   Mathematical models including quantitative structure-permeability relationships (QSPRs) 76   Human skin equivalent models 77   Chromatographic models 78 
In vitro models using synthetic membranes 79 
For the past ten years, there has been general acceptance of the Organisation for Economic 80 
Cooperation and Developments (OECDs) guidelines for in vitro methods in the examination of skin 81 
permeation and distribution (No. 428). These guidelines set out a basic study design and requirements 82 
to justify certain experimental parameters such as membrane choice, dose concentration and assay 83 
validations. For all major in vitro systems, the basic experimental setup includes a phase to replicate 84 
the skin surface, a separating membrane barrier and a solution phase to replicate beneath the skin – 85 
see reference (19) for a full description. In all studies the sample is applied to the skin surface (donor) 86 
phase, given time to pass through the membrane barrier and extracted from the second (receptor) 87 
phase at given time intervals to then be analysed to determine concentration. From such data it is 88 
possible to calculate a permeability coefficient, assuming ‘infinite’ doses are considered, most 89 
commonly using a Franz-type diffusion cell or flow-through cell design (20). Modifications of this 90 
set-up have been published, such as a novel diffusion cell which allows study of membrane diffusion 91 
processes without the need for sampling of the receiver compartment (21). The proposed method 92 
employs a spectrophotometer quartz cuvette containing the receiver solution with a small PTFE cap 93 
containing the membrane and an injection port through which compounds can be applied. The 94 
obvious benefit of this more advanced system is the non-invasive nature of obtaining permeation data 95 
and its potential for continual and automated permeation measurements. Other researchers have 96 
published methods to study membrane transport processes that also avoid the necessity to remove 97 
samples such as surface enhanced Raman scattering (SERS) which again provides non-invasive 98 
advantages compared with traditional methods (22). More recently, analysis has begun to move away 99 
from the standard choice of UV-based techniques to include alternatives, such as attenuated total 100 
reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) and target factor analysis where it 101 
was found data could be successfully deconvoluted and different components of formulations 102 
identified (23).  103 
Drug diffusion studies are often used to measure the movement of selected compounds 104 
through a specific membrane, chosen by the researcher to mimic the in vivo scenario. Data acquired 105 
from such studies can then be correlated with that obtained from human clinical trials. In some cases 106 
the membrane selected for use may be of human origin (24, 25), although this is infrequently 107 
undertaken for two main reasons, namely economic constraints and data variability. Skin for these 108 
studies is often acquired following surgical procedures. Samples can vary significantly in thickness 109 
and composition (often frozen for transport), which is not always a problem (26-28), although, it has 110 
been reported to be an issue in many studies - as highlighted in the low reproducibility in data 111 
obtained (29). Rather than using human skin, some experimental work has employed animal skin as 112 
the membrane to separate the two phases. Again, this can lead to significant variability in data 113 
depending upon the sample location and the species used. For example, one particular study compared 114 
permeability coefficients for several commonly used drugs between hairless mouse skin and human 115 
skin and found the human skin values to be far lower than the mouse skin, exemplifying the poor in 116 
vitro-in vivo correlation (30).  117 
Although the economic costs of using animal skin are far lower than those for human skin, 118 
issues of data variability and ethical concerns have led scientists to develop many forms of synthetic 119 
membranes to overcome these problems. The vast majority of work in the field of synthetic 120 
membranes for transdermal and topical delivery studies has focused on the use of polymeric 121 
membranes (31), such as silicone-based membranes (32). Such membranes are ideal for replacing ex 122 
vivo skin as they can be synthesised to a desired thickness, are easy to handle and store, are 123 
comparatively cheap, are inert, and provide reproducible data. For all of these advantages, many 124 
studies have considered the suitability of replacing both human and animal skin with silicone 125 
membrane for in vitro studies, attempting to develop a successful in vitro – in vivo relationship to 126 
ensure such a membrane can be truly considered as an acceptable model system for the prediction of 127 
transdermal permeation in humans. Silicone-based membranes, such as polydimethylsiloxane 128 
(PDMS) are generally hydrophobic in nature, and provide a rate limiting step in drug permeation. 129 
Many of the topical drug delivery diffusion studies that have employed synthetic membranes are 130 
summarised in reference (31), illustrating the vast range available to researchers, from the standard 131 
silicone membrane, to polyethylene to cellulose ester. The membranes exhibit variability in their pore 132 
size, thickness and permeation resistance, thus affecting the rate and extent of drug penetration, which 133 
in turn leads to variations in calculated permeability coefficients. Some studies involve porous 134 
membranes in which case pore size in particular can be an incredibly influential factor, indicated by 135 
its alternative name – ‘molecular weight cut-off’, identifying the relationship between the size of the 136 
permeating molecule and the likelihood of permeation occurring. More specifically, porosity and 137 
tortuosity are frequently used to define porous synthetic membrane structures, which is vital when 138 
considering a porous membrane for in vitro studies.  139 
For all synthetic membranes, the particular physicochemical properties displayed by the 140 
membrane are mainly derived from the preparation method used, thus it is vital to have a reproducible 141 
manufacturing technique to avoid inter-experimental variability. For a non-porous membrane, 142 
permeation occurs in three stages – firstly the permeant dissolves in the membrane, secondly it 143 
diffuses through the membrane and finally, it emerges from within the membrane. This process 144 
follows Fick’s First Law of diffusion and permeation depends upon interactions between the 145 
compound and the membrane, in a similar manner to that seen between the compound and 146 
hydrophobic stratum corneum. 147 
Synthetic membranes are used in transdermal studies for two specific purposes; in vivo 148 
prediction and qualitative analysis. The latter is routinely measured using Franz-type diffusion cells as 149 
part of the quality control process to ensure new products display comparable diffusion profiles to 150 
those previously measured. The low cost and simplicity of the technique are ideal to ensure batch to 151 
batch consistency in formulations with minimal complications from biological variations that would 152 
be encountered with in vivo analysis. The former, i.e. the use of synthetic membranes to predict 153 
transdermal permeation in vivo, is open to more debate as researchers attempt to correlate the 154 
experimental data obtained with that expected from clinical studies. Through simplifying the 155 
membrane structure to a synthetic material increases the reproducibility of the data yet also in turn, 156 
removes the finer detail, such as more complex phenomena including metabolic epidermal activity. 157 
For example, it has been found that introducing metabolic inhibitors can have a pronounced effect on 158 
transdermal drug delivery (33), i.e. implying synthetic membranes may not be complex enough for 159 
such studies. However, many feel the benefits from such a compromise outweigh the costs, for 160 
example, even when replicating inflamed skin (34). It has been suggested that artificial membranes 161 
can only provide a useful forecast of in vivo transdermal delivery when the following criteria are met 162 
(35): 163 
o Passive diffusion through the stratum corneum is the major resistance to transport 164 
o The drug under investigation is known to be metabolically inert and not specifically 165 
bound in viable skin 166 
o The formulation does not contain a permeability enhancer which can interact with skin 167 
but not membrane and 168 
o In vivo experiments can be performed and correlated with in vitro results. 169 
 Investigations into the formulation aspects of the applied product have further confirmed the 170 
variability that can occur as a result of modifications in the chemical nature of the excipients selected 171 
(36-41). For example, research within our own group has found substantial effects based upon the 172 
simple addition of an anionic surfactant to the formulation, yet no effect upon the addition of a 173 
cationic surfactant (37). For example, a study into the influence of ethanol on the solubility, ionisation 174 
and permeation characteristics of a model drug (ibuprofen) found the flux through silicone 175 
membranes increased up to a maximum of 100 % ethanol yet, in human skin, flux was optimal at 176 
lower ethanol percentages (42). Following on from this study, researchers investigated the influence 177 
of propylene glycol (PG) using binary (PG:water) and ternary (ethanol:PG:water) solvent systems. 178 
Fluxes were maximum for 70:30 PG:water systems in silicone membrane; however, for experiments 179 
conducted with skin, the flux of ibuprofen systematically increased with increasing amounts of PG. 180 
For silicone membrane, the flux values of ibuprofen from ternary systems were higher than the 181 
highest values observed from the binary systems (43). Furthermore, permeation from mineral oil 182 
(MO), Miglyol® 812 (MG) and binary mixtures of MO and MG found the solubility of ibuprofen to 183 
be higher in MG than in MO. However, the permeation of ibuprofen from the pure vehicles and 184 
combinations of both was comparable in silicone membrane. Additionally, when the permeation of 185 
various hydrophilic and lipophilic vehicles was considered, a trend between flux values for the model 186 
membrane and skin was evident suggesting that silicone membrane may provide information on 187 
qualitative trends in skin permeation for vehicles of diverse solubility and partition characteristics 188 
(44).  Other studies have also demonstrated the effects excipients may have on drug solubility and 189 
permeation. One such example highlights this phenomenon where drug-polymer dispersions were 190 
clearly shown to improve flux for a poorly soluble drug, namely artemisinin (45). However, not all 191 
excipients incorporated within transdermal formulations are capable of influencing drug transport or 192 
permeating with the drug. For example, concerns had been raised about the possible implications that 193 
dermal exposure to nanoparticles may have for human health. The maximum flux of such systems 194 
was calculated, and the results confirmed that they are too large to permeate skin (46). Based on all of 195 
these findings it can be said that the permeation of compounds through skin may be affected by the 196 
additional compounds within a formulation, but determining the specific details of such an influence 197 
is not a simple matter. 198 
Some researchers have attempted to expand the applicability of using synthetic membranes to 199 
maximise their suitability for permeation studies. Ng et al. (47) investigated diffusion rates of 200 
ibuprofen across thirteen membranes finding variable drug fluxes, thus categorising the membranes 201 
into high-flux and low-flux membranes. For example, they found that porous membranes derived 202 
from various polymers demonstrated different degrees of diffusional resistance to ibuprofen, 203 
indicating that there would be wide discrepancies in results obtained from different laboratories using 204 
different porous membranes. They suggest that when selecting a membrane for formulation analysis it 205 
is best to choose one with high porosity, a tortuosity of one and be relatively thin. Furthermore, the 206 
compatibility of the membrane with the donor, and receptor, components must be considered, along 207 
with the cost effectiveness of the membrane. In transdermal permeation studies, it is common to 208 
measure drug release rates by monitoring the cumulative mass of drug appearing in the receptor 209 
solution (MR). However, if a synthetic membrane is placed between the donor and receptor phases 210 
then there is a delay in drug transfer, and MR is not immediately linear with respect to time. As a result 211 
of this non-linearity it is vital that permeation studies are conducted for long enough that the 212 
relationship achieves linearity to ensure calculated drug diffusivity values are correct (48).  213 
 More complex synthetic membranes have shown promise to provide a better representation of 214 
the stratum corneum barrier, for example, using a polydimethylsiloxane-polycarbonate block 215 
copolymer membrane (Carbosil) (49). In one such study, permeability was examined as a function of 216 
permeant molecular weight, melting point, solubility, partition coefficient and diffusivity for 14 drugs 217 
covering a wide range of chemical structures. It was found that Carbosil provided a higher drug 218 
solubility, and consequently, higher permeability compared with human skin. However, by varying 219 
the block copolymer membrane the diffusivity could be significantly modified, implying a more 220 
appropriate in vivo model can be created. Further work in this field has led researchers to establish the 221 
importance of considering membrane hydration in such studies (50). In another study two synthetic 222 
lipid models (designed to replace human stratum corneum) were studied to investigate the impact of 223 
volatile organic chemicals on the molecular organization of the skin barrier lipids (51). The models 224 
built upon previously developed self-assembled lipid membranes, which have a composition and 3D 225 
organisation similar to those of the in vivo lipid matrix. In one model the target chemicals were 226 
incorporated in the lipids before their self-assembly, and in the other one they were applied on top of a 227 
preformed lipid membrane. Encouragingly, the dose-dependent effects of the chemicals on the lateral 228 
molecular organization in the models were qualitatively identical to those observed by infrared 229 
spectroscopy in human skin. The study concluded that these model systems are suitable for in vitro 230 
studies in the areas of skin biophysics, dermatology, transdermal drug delivery, and risk assessment. 231 
Natural membranes have also been considered to measure permeation for model drugs, 232 
including those of different molecular weights and lipophilicities using Franz-type diffusion cells. For 233 
example, membranes can be taken from the outer layers of peach and tomato, the middle layers of 234 
onions and with the inner layer of eggs (52). Encouragingly, results showed that the rate and amount 235 
of diclofenac permeated through onion skin, metronidazole through tomato skin and erythromycin 236 
through egg membrane was not significantly different from that with human skin. From these results 237 
it was concluded that natural membranes have pores and channels with hydrophilic properties, 238 
permitting permeation of small to middle size hydrophilic drugs to diffuse in a manner similar to 239 
human skin. Other natural membranes have also been considered for transdermal studies, and 240 
comparisons made with the more standard membrane options (53). 241 
Within the last ten years a parallel artificial membrane permeability assay (PAMPA) has been 242 
developed for the rapid determination of passive transport permeability in vitro, gaining acceptance in 243 
pharmaceutical research. In PAMPA, a 96-well filter plate coated with a liquid artificial membrane is 244 
used to separate two compartments:  one containing a buffer solution of compounds to be tested 245 
(defined as donor compartment) and the other containing an initial fresh buffer solution (defined as 246 
acceptor compartment). In one of the earliest studies, isopropyl myristate, silicone oil, and mixtures of 247 
the two components were immobilised on filters and tested as liquid supported membranes in 248 
PAMPA to evaluate their potential to mimic the human skin barrier (54). Effective permeability 249 
coefficients (Pe) were determined for a set of compounds using the PAMPA technique and compared 250 
with the corresponding human skin permeability coefficient values (Kp). A good correlation between 251 
Pe and Kp was found for compounds tested through a membrane consisting of 70 % silicone and 30 % 252 
IPM. Moreover, a positive correlation between the membrane retention of compounds and stratum 253 
corneum/water partition coefficients (PSC) was established, implying PAMPA can be used for the 254 
prediction of passive human skin permeability coefficients. Further studies in this area have further 255 
confirmed the validity of the technique (55) and, along with the low cost, versatility and good 256 
reproducibility (56) of the system ensure it is a feasible membrane mimic system. In 2012, Sinko et al. 257 
(57) attempted to match the permeability of the rate-limiting barrier in human skin using synthetic 258 
analogs of the ceramides present in the stratum corneum. The final skin-PAMPA membrane lipid 259 
mixture (certramide, free fatty acid, and cholesterol) was selected and optimized based on data from 260 
three different human skin databases and the final model was found to correlate well to all of the 261 
databases. The reproducibility of the skin-PAMPA model was investigated and compared to that of 262 
other PAMPA models, confirming it to be a quick and cost-effective research tool that can serve as a 263 
useful model of skin penetration in pharmaceutical and cosmetic research. More recently, several 264 
variations of the artificial membrane employed in the PAMPA study system were analysed (isopropyl 265 
myristate (IPM), certramides and Strat-M™) (58). These were evaluated for their ability to predict the 266 
skin permeability of caffeine, cortisone, diclofenac sodium, mannitol, salicylic acid and testosterone 267 
applied in propylene glycol, water and ethanol as unsaturated and saturated concentrations. Resultant 268 
absorption data was compared to skin diffusion cell data. The correlations between membrane and 269 
diffusion cell data from saturated and unsaturated concentrations were rather low, although this 270 
relationship improved when only saturated concentrations were evaluated. These results suggest the 271 
potential of PAMPA as an initial screening approach to assist in narrowing the selection of 272 
formulations to be evaluated, thereby assisting in the development of new topical formulations. Based 273 
on these findings and others in the field (59), PAMPA has been accepted as a suitable skin mimic 274 
system that can provide significant benefits for in vitro analysis compared with more simplistic 275 
artificial membrane systems. Furthermore, results of PAMPA permeability and retention have been 276 
used to create mathematical models that could be employed for the design of novel derivatives with a 277 
favorable skin retention/permeability ratio. 278 
In summary, in vitro models for predicting transdermal permeation have been thoroughly 279 
studied over the years, including the effects of factors such as the formulation and choice of 280 
membrane system. In recent years, researchers have successfully developed more complex artificial 281 
membrane systems that are able to provide precise and accurate predictions of transdermal permeation 282 
without the need to use human or animal skin. The benefits of such non-in vivo systems are 283 
significant, for economic, reproducibility and ethical reasons amongst others. 284 
 285 
Mathematical models including quantitative structure-permeability relationships (QSPRs) 286 
Using models to predict the permeability of a compound through skin is particularly complex 287 
as a result of the intricate nature of the structures and mechanisms that dictate the delivery pathway. 288 
While the stratum corneum barrier, which serves as the major rate-limiting component to skin 289 
penetration for most drugs, has been the focus of most penetration models, much less is known about 290 
transport beyond this stage, and about transport via the appendageal routes. When modelling skin 291 
transport processes quantitatively, it is usual to consider the particular physiological regions of 292 
interest as compartments (60). Drug levels within the compartments can be modelled as a single time-293 
dependent value, or as function of both position within that compartment (usually skin depth) as well 294 
as time. For the latter choice, drug transport within the compartment may be modelled using partial 295 
differential equations that describe the effects of drug diffusion, convection, elimination and 296 
metabolism (61). Models usually concern the steady-state flux of drug into the skin and related 297 
quantities such as the permeability coefficient and the maximum steady-state flux, the lag time 298 
between drug application and attainment of the steady state; the clearance of drug through excretion; 299 
and drug concentrations in the various skin layers, circulation, or other tissues (62). Theoretical 300 
permeation models have become more and more complex over the past fifty years. For example, 301 
ranging from simple models that consider the stratum corneum as a single compartment to those more 302 
complex that consider the structural characteristics of skin, including contributions from the lipidic 303 
components. Complexity may not always be necessary, for example, one particular study in 2011 304 
found that only by using a two-compartment dermal clearance model that includes both diffusion and 305 
transport by dermal blood vessels consistency was obtained between observed and previously 306 
described in vivo literature data (63).  307 
In general, two types of mathematical models have been developed to predict transdermal 308 
permeation, i.e. those based on the properties of the compound permeating or those based on the 309 
properties of the skin being permeated. Whereas the first is focused on predicting penetration through 310 
the skin from a solute's physicochemical properties, the second type models transport processes in 311 
skin layers using appropriate equations with the specific aim of predicting the concentration of a given 312 
solute in viable skin tissues (64). In general, it has been found that models are an important tool for 313 
accurate valuation of skin toxicity experiments, estimation of skin toxicity and for developing new 314 
formulations for skin disease therapy. Being aware of toxicological responses is important for a 315 
variety of reasons, for example when considering likely exposure of workers to certain compounds 316 
(65, 66). However, more comprehensive mathematical models of drug transport in skin, especially 317 
those based on more physiologically detailed mechanistic considerations of transport processes, are 318 
required to further enhance their role in assessing skin toxicology.  319 
Models of skin absorption have attracted significant interest in the last two decades following 320 
the publication of two models for quantitative analysis (67, 68) in which permeability was related to 321 
physicochemical properties of the permeant. Prior to that, the majority of studies tended to focus on 322 
only small groups of compounds and the relationship with  hydrophobicity where, unsurprisingly, it 323 
was found an increase in hydrophobicity led to an increase in permeation. Expanding consideration to 324 
a wider range of permeant characteristics, for example hydrogen bonding, melting point and 325 
ionization properties, led to the development of more ‘refined’ models, summarized in references (35) 326 
and (69).  327 
Fitting experimental data to create statistically derived equations creates quantitative 328 
structure-permeability relationship (QSPR) models. Most QSPR models consider skin permeation 329 
through tortuous lipid pathways that may under-predict skin permeability of hydrophilic solutes, by 330 
several orders of magnitude. As a result of this researchers have begun, in recent years, to consider 331 
including aqueous pathways to improve the predictive abilities of permeation for hydrophilic solutes 332 
(70). As a further complication, some compounds are known to undergo metabolism within the skin 333 
thus several models also take into account contributions from metabolite permeation (71). As a variety 334 
of physicochemical parameters are known to potentially impact on drug-release profiles, researchers 335 
have developed mathematical models that take such parameters into account, for example taking into 336 
consideration the effects of dosing level, the type of vehicle (i.e. formulation), concentration profiles 337 
(72), solubility in particular solvents (73) and ionisation state of the permeant (74).  Although these 338 
models tend to be based on several assumptions (for example: that steady-state transport across the 339 
skin is achieved even though a finite dose was applied) they have been shown to be successful for 340 
predictive ability in certain situations. Combining calculations of skin concentrations within two 341 
diffusion layers and results from silicone membrane permeations studies has led to precise predictions 342 
of in-skin concentrations (75). A few studies have evaluated the correlation between skin permeability 343 
predictive models and human in vivo data, with mixed findings, ranging from one study concluding 344 
most models correlated well with the in vivo data (76), through to another study that declared models 345 
were not suitable for accurately predicting permeation but were able to effectively rank the permeants 346 
and could help to select candidate molecules for in vitro screening (77). 347 
In summary, mathematical models of transdermal permeation play an essential role in the 348 
investigation of epidermal and dermal transport of compounds, despite their limitations based on 349 
assumptions introduced to simplify the process, they are useful tools for data analysis, and predictions 350 
for dermal solute penetration (78). 351 
 352 
Human skin equivalent models 353 
 As researchers have strived to create an in vitro model as close as possible to human skin, 354 
many have viewed the development of three dimensional tissue models to be the ultimate goal. A 355 
major drive towards this aim has arisen from the cosmetic industry with the necessity to replace 356 
animal testing therefore creating a regulatory reason to provide human skin equivalents. This research 357 
is now beginning to be adopted by pharmaceutical scientists as applications for measuring transdermal 358 
permeation are realised. Although attempts have been made to produce a reliable model for over 359 
twenty years, as recently as 2001 there was a belief that such models were not useful for in vitro 360 
penetration studies compared with other existing methods. For example, one particular study found far 361 
higher flux and skin concentration values using a living skin equivalent compared with human skin 362 
(79). However, more recently, human skin equivalents have been described as an ‘excellent’ tool, for 363 
example to study water distribution following application of moisturiser (80), and many view them as 364 
the future of transdermal permeation studies in vitro  (81-85). 365 
 Models formed using only one cell type, known as reconstructed human epidermis (RHE), are 366 
used for their high level of reproducibility, yet can be viewed as too simplistic for consideration as a 367 
complete human skin equivalent system. The European Centre for the Validation of Alternative 368 
Methods has validated several RHE models for skin corrosion and irritancy studies confirming their 369 
place as a viable replacement to other methods to obtain such data. To conform to the necessary 370 
criteria the test systems must pass minimum standards relating to viability, barrier function, 371 
morphology, reproducibility and quality control. Analytical techniques to verify these criteria include 372 
infrared and Raman spectroscopy (86) and confocal laser scanning microscopy (87).  Researchers 373 
have attempted to apply RHE models to determine drug permeation and one such study found values 374 
exceeded those for human epidermis yet, showed a tendency towards a lower level of variability (88). 375 
Commercially available examples include SkinEthic®Rhe and Episkin®, both developed by L’Oreal, 376 
France and more recently, oral epithelium models such as EpiOral™ (MatTek Corporation, USA). 377 
Full thickness models consist of more complex systems, for example incorporating additional 378 
cell types such as melanocytes and stem cells. By increasing the complexity of the models, through 379 
incorporation of additional components, researchers believe they more truly replicate in vivo scenarios 380 
yet it must also be remembered they decrease the reproducibility and can significantly increase 381 
experimental costs. A detailed summary of the available state-of-the-art models can be found in 382 
reference (89). Full thickness models are composed of both dermal and epidermal layers, i.e. creating 383 
a bilayer structure similar to that found in human skin. More and more complex systems are 384 
continually being created, such as by the creation of a viable adipose layer (90), allowing researchers 385 
to resolve more complex dermatological issues (91). Commercially available examples include 386 
RealSkin® (L’Oreal, France) and AST2000 (CellSystems Biotechnologie GmbH, Germany) (92).  387 
Unsurprisingly, there are limitations even with three dimensional skin models which must be 388 
addressed when considering the use of such systems for in vitro permeation determination. Firstly, 389 
most relevant to cosmetic applications, is the inability of the models to generate stratum corneum, as 390 
they consist of primary cells with a limited lifespan and, a lack of cells of the immune system. It has 391 
been proposed that immortalised cell lines could improve the reproducibility and consistency of skin 392 
models reducing intra and inter-laboratory variations (93). Secondly, some studies have reported a 393 
dissimilar barrier function of human skin equivalents. For example, one such study found that the 394 
models were able to mimic many aspects of human skin but, differed in their barrier properties (94), 395 
implying they would not be suitable for permeation studies. Finally, the limited lifespan of these 396 
living models (~ eight weeks), reduces their suitability for experimental study, although some work 397 
has been conducted in this area to improve this situation, in one case increasing their availability for 398 
up to twenty weeks (95). 399 
With such a rapid expansion of work (and commercially available products) in this area it is 400 
inevitable that the future of skin mimic systems incorporates aspects of RHE or full thickness models 401 
to some extent. 402 
 403 
Chromatographic models 404 
 High-performance liquid chromatography (HPLC) has been utilised and adapted to predict 405 
skin permeability data, mainly in the last twenty years. Recently, the ability of a selection of 406 
chromatographic systems to model human skin permeation has been evaluated and tested, by 407 
correlating experimental data with in vivo data for a representative set of neutral solutes (96). It was 408 
reported for the six systems (including the classic octanol-water partition system) that the HPLC 409 
systems with C18 columns are the closest to the human skin permeation system whereas the micellar 410 
electrokinetic chromatographic (MEKC) systems were most different – based on distance parameters. 411 
However, the study also declared that error arising from the original skin permeability data is quite 412 
significant and the variance from the C18 systems was possibly too high to provide precise 413 
estimations of human skin permeability coefficients. This can be improved by introducing the solute’s 414 
volume as an additional variable, resulting then in correlation models with good predictive abilities to 415 
estimate permeation for untested solutes.  416 
 A great deal of interest has been shown in one particular type of column used in HPLC, the 417 
so-called immobilised artificial membranes (IAMs). IAMs are synthesised by covalently binding 418 
biologically relevant phospholipids to the surface of silica, such as attaching monolayers of 419 
phosphatidylcholine to a propylamine silica support. For some years immobilised stationary-phase 420 
liquid chromatography has been considered a potential in vitro technique (97), including studies to 421 
examine its potential for predicting transdermal transport across neutral, basic, acidic and amphoteric 422 
compounds (98). Interestingly, the findings indicated that IAM and partition coefficient values are 423 
complementary and not alternative parameters whose combination yields more useful data than either 424 
factor alone. Some researchers have taken the use of IAMs towards very specific applications, for 425 
example through the physical immobilisation of keratin or collagen on the silica support, permitting a 426 
comparison of the keratolytic properties of compounds (99, 100). Other forms of chromatography 427 
have also been explored, for example liposome electrokinetic chromatography (LEKC) (101). LEKC 428 
has been described as a promising simple method to predict drug penetration based on quantitative 429 
retention-activity relationships (QRARs) constructed between skin permeability coefficients and 430 
retention values. 431 
Combining the desire to mimic the biological environment with a highly predictable 432 
analytical technique has resulted in the development of biopartitioning micellar liquid 433 
chromatography (MLC). In MLC, the mobile phase consists of surfactant molecules above the critical 434 
micellar concentration, i.e. in micellar form. A compound is then injected into this mobile phase and 435 
the retention time recorded over a series of concentrations. For some time, researchers have 436 
appreciated the value of biopartitioning micellar separation methods for modelling drug absorption 437 
(102), and more specifically, for predicting skin permeability (103). Within the last twelve months our 438 
research group has developed, evaluated and published a method to measure the chromatographic 439 
retention of drugs which can then be used to predict skin permeability using micellar chromatography, 440 
achieving high levels of reliability (104). In our study, we looked at a series of model compounds and 441 
found that the replacement of a traditional physicochemical parameter, namely the octanol-water 442 
partition coefficient, with a chromatographically determined value resulted in a quantitative value that 443 
was robust to variation, i.e. a suitable method to predict transdermal permeation.  The advantages of 444 
this method are numerous, and of particular benefit is the high level of predictive capability that has 445 
not been seen in other studies.   446 
In summary, chromatographic methods appear to show promise using a variety of 447 




 When undertaking a study to investigate transdermal permeability, there are many options to 452 
consider, and researchers tend to choose techniques that are most suited to their intended purpose, 453 
availability, previous experience or economic constraints. The majority of the techniques currently 454 
available have been shown to be suitable for ranking a series of compounds (or formulations), yet do 455 
not provide an in vitro-in vivo correlation that suggests they can be used as a pure replacement. For 456 
many reasons this is the ultimate aim of such studies and work continues to develop systems that can 457 
either mimic skin to permit experimental data to be measured (i.e. using synthetic membranes or 458 
human skin equivalents), or predict permeation (i.e. using chromatographic methods or mathematical 459 
models). Development of the latter will undoubtedly lead to the availability of software that can 460 
simulate absorption of dose into the skin, diffusion through the skin and clearance into blood which 461 
can be used in the development of pharmaceuticals, cosmetics, household products and 462 
agrochemicals. A very limited number of such packages are already available, such as the Skin-in-463 
Silico™ software (Xemet, Finland), yet it is highly anticipated that this is the likely direction of 464 
transdermal studies in the future, thus completely replacing the need for animal testing. Clearly, it can 465 
be seen that only through understanding the physicochemical properties of the compound under 466 
investigation and the structure of the skin is it possible to quantify transdermal permeation. For this 467 
reason, it will no doubt continue to be a combination of in vitro experimental measurement and 468 
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